Cristaudo A, Foddis R, Vivaldi A, et al.
Clin Cancer Res. 2007;13(17):5076-5081.
Cristaudo and colleagues evaluated the MESOMARK assay (SMRP) in patients from two regions of Italy where there is a high exposure to asbestos. The study included subjects with mesothelioma (n=107), lung cancer (n=215), benign respiratory disease (n=130) and a control group (n=262). A 1.0 nM cutoff was used in this patient population resulting in a sensitivity and specificity for the assay similar to the reports of other researchers at 68.2% and 80.5% respectively. SMRP values were significantly elevated in patients diagnosed with mesothelioma and a decrease in values was observed following surgery. The key finding of this research is the association of SMRP values in serum and prognosis. The researchers showed that at an SMRP value >1.0 nM the median survival was 11.7 months less than those who had an SMRP value <1.0 nM. In conclusion the research indicates that SMRP may be useful in clinical use to differentiate lung cancer versus mesothelioma, as well as in monitoring response to therapy and prognosis.